Three proteasome inhibitors (PIs) are approved for patients with multiple myeloma (MM): Bortezomib, a first-in class PI, fights both newly diagnosed and relapsed/refractory MM (RRMM); carfilzomib, a ...

American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report ...

In recognition of September as Prostate Cancer Awareness Month, Daniel Petrylak, MD, professor of oncology and urology at ...

Success as An Anti-Cancer Agent Has Fueled Efforts to Discover Proteasome Inhibitors That Raise Proteins Levels with Beneficial Effects The ubiquitin proteasome system (UPS) provides a mechanism for ...

At the recent Celebration of Native Mass Spectrometry in Oxford, we caught up with Michal Sharon to talk about her research and the fascinating evolutionary history of the 20S proteasome. Would you ...

The proteasome, that large subcellular grinder that recycles protein, plays a major role in localized degeneration of axons, according to a report in this week's Neuron. Such neuronal damage typically ...

Dr Chari discusses the use of proteasome inhibitors [PIs] in the treatment of multiple myeloma and the differences among the available agents. Transcript Ajai Chari, MD: The PI [proteasome inhibitor] ...

Developing small molecules that activate a subset of the body’s proteasomes to degrade defective proteins could be an effective way to treat neurodegenerative diseases and other complex disorders ...

Ubiquitylated substrate recognition during ubiquitin/proteasome-mediated proteolysis (UPP) is mediated directly by the proteasome subunits RPN10 and RPN13 and indirectly by ubiquitin-like (UBL) and ...

American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report ...